<div id="readability-page-1"><div><p><span></span></p><ul><li>Spruce Biosciences Inc  is expected to  show a fall in quarterly revenue when it reports  results on November 10 (estimated) for the period ending September 30 2025</li><li></li><li>​LSEG's mean analyst estimate for Spruce Biosciences Inc is for a loss of $13.93 per share. </li><li>The current average analyst rating on the shares is &#34;buy&#34; and the breakdown of recommendations is 1 &#34;strong buy&#34; or &#34;buy,&#34; 1 &#34;hold&#34; and no &#34;sell&#34; or &#34;strong sell.&#34;  </li><li>The mean earnings estimate of analysts was unchanged in the last three months. ​</li><li>Wall Street's median 12-month price target for Spruce Biosciences Inc is $132.00, about 9.6% above its last closing price of $119.29</li></ul></div></div>

SPRBX

SPRBD

SPRB

<p>Spruce Biosciences Inc is anticipated to report a loss of $13.93 per share for the quarter ending September 30, 2025, with results expected on November 10. Analysts maintain a "buy" rating, with one strong buy, one hold, and no sell recommendations. The median 12-month price target is $132.00, reflecting a 9.6% increase from the last closing price of $119.29.</p>

Spruce Biosciences Inc expected to post a loss of $13.93 a share - Earnings Preview